Who can participate?

Inclusion Criteria:

• Histologically confirmed diagnosis of a locally advanced or metastatic solid tumor and the individual has progressed on standard of care therapy, cannot tolerate standard of care therapy, refused standard of care therapy, or there is no standard of care therapy.
• Age 18 years or older at the time of informed consent
• Life expectancy >12 weeks
• ECOG performance status of 0 or 1
• Have at least one measurable and injectable tumor that is accessible by transcutaneous administration

Exclusion Criteria:

• Prior oncology therapy (chemotherapy, immunotherapy, biological therapy) or use of an investigational agent or an investigational device within 21 days or 5 half-lives before administration of first dose of KB707, whichever is shorter
• The subject is pregnant, nursing, or plans to become pregnant during study treatment and through three months after the last dose of KB707
• Have known history of positive human immunodeficiency virus (HIV 1/2)